Identification and cost of adverse events in metastatic breast cancer in taxane and capecitabine based regimens

SpringerPlus

Volumn 3, Issue 1, 2014, Pages 1-8

  Hansen, Ryan N ^a   Ramsey, Scott D ^a,b   Lalla, Deepa ^c   Masaquel, Anthony ^c   Kamath, Tripthi ^c   Brammer, Melissa ^c   Hurvitz, Sara A ^d   Sullivan, Sean D ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c GENENTECH INC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse effects; Antineoplastic agents; Breast neoplasms; Costs and cost analysis

Indexed keywords

EID: 84903997350     PISSN: None     EISSN: 21931801     Source Type: Journal    
DOI: 10.1186/2193-1801-3-259     Document Type: Article

References (18)

1. Beslija S, Bonneterre J, Burstein HJ, Cocquyt V, Gnant M, Heinemann V, Jassem J, Köstler WJ, Krainer M, Menard S, Petit T, Petruzelka L, Possinger K, Schmid P, Stadtmauer E, Stockler M, van Belle S, Vogel C, Wilcken N, Wiltschke C, Zielinski CC, Zwierzina H: Third consensus on medical treatment of metastatic breast cancer. Ann Oncol 2009, 20: 1771-1785.
2. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999, 17: 485-493.
3. Chu E, Schulman KL, Zelt S, Song X: Costs associated with complications are lower with capecitabine than with 5-fluorouracil in patients with colorectal cancer. Cancer 2009, 115: 1412-1423.
4. Craver C, Gayle J, Balu S, Buchner D: Clinical and economic burden of chemotherapy-induced nausea and vomiting among patients with cancer in a hospital outpatient setting in the United States. J Med Econ 2011, 14: 87-98.
5. Guerin A, Lalla D, Latremouille-Viau D, Yu AP, Wu EQ, Brammer M, Hurvitz SA: Costs associated with chemotherapy-related complications in the treatment of metastatic breast cancer in a real-world setting. J Clin Oncol 2011., 29(15): (May 20 Supplement; Abstract 602).
6. Hurvitz S, Guerin A, Brammer M, Guardino E, Zhou ZY, Kaminisky M, Wu EQ, Lalla D: Comprehensive investigation of adverse-event related costs in patients with metastatic breast cancer treated with first- and second-line chemotherapies. 2012. Presented at the American society of clinical oncology annual meeting, Chicago, IL, June 1-5, 2012.
7. Hwang SY, Chang SJ, Park BW: Does chemotherapy really affect the quality of life of women with breast cancer?J Breast Cancer 2013, 16: 229-235.
8. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML, Ravdin PM: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 2005, 23: 5542-5551.
9. Kayl AE, Meyers CA: Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obstet Gynecol 2006, 18: 24-28.
10. Metastatic Breast Cancer Network: Statistics for metastatic Breast cancer, 2013. 2010. http://mbcn. org/education/category/most-commonly-used-statistics-for-mbc/.
11. National Comprehensive Cancer Network: NCCN clinical practice guidelines in oncology: breast cancer, version 3. 2013. http://www. nccn. org/professionals/physician_gls/f_guidelines. asp#breast.
12. SAS Institute, Inc: SAS version 9. 3. SAS Institute, Inc, Cary, NC; 2012. http://www. sas. com/.
13. Stokes ME, Muehlenbein CE, Marciniak MD, Faries DE, Motabar S, Gillespie TW, Lipscomb J, Knopf KB, Buesching DP: Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. J Manag Care Pharm 2009, 15: 669-682.
14. Taxol: (paclitaxel) [package insert]. Bristol-Myers Squibb, Princeton, NJ; 2011.
15. Taxotere: (docetaxel) [package insert]. Sanofi-Aventis US LLC, Bridgewater, NJ; 2013.
16. US Dept. of Labor, Bureau of Labor Statistics: Consumer price index-all urban consumers: US medical care. http://www. bls. gov/cpi/#tables.
17. Vera-Llonch M, Weycker D, Glass A, Gao S, Borker R, Qin A, Oster G: Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality. BMC Cancer 2011, 11: 250-257.
18. Xeloda: (capecitabine) [package insert]. Genentech USA, Inc, South San Francisco, CA; 2011.